Products for Research Use Only
RegisterLogin

Risdiplam (Standard)

CAT: 0804-HY-109101R-04Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109101R-04Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Risdiplam (Standard) is the analytical standard of Risdiplam. This product is intended for research and analytical applications. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels[1].
CAS Number
1825352-65-5
Product Name Alternative
RG7916 (Standard) ; RO7034067 (Standard)
UNSPSC
12352005
Target
DNA/RNA Synthesis; Reference Standards
Type
Reference Standards
Related Pathways
Cell Cycle/DNA Damage; Others
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/risdiplam-standard.html
Smiles
O=C(C=C(C(C=C1C)=NN2C1=NC(C)=C2)N=C3C=C4)N3C=C4N(CCN5)CC65CC6
Molecular Formula
C22H23N7O
Molecular Weight
401.46
References & Citations
[1]Poirier A, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018 Nov 29;6 (6) :e00447.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Chemical Information

Risdiplam

Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). It increases systemic SMN protein concentrations by improving the efficiency of SMN2 gene transcription. This mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene therapy [onasemnogene abeparvovec], whereas risdiplam offers the ease of oral bioavailability. Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA). Set to be substantially cheaper than other available SMA therapies, risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless of severity or type.

CAS Number1825352-65-5
PubChem CID118513932
IUPAC Name7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one
Molecular FormulaC22H23N7O
Molecular Weight401.5
XLogP0.5
Topological Polar Surface Area78.1
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count6
Rotatable Bond Count2
Heavy Atom Count30
Formal Charge0
Complexity886
SMILES
CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6
InChI
InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3
InChIKey
ASKZRYGFUPSJPN-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Risdiplam
CAS: 1825352-65-5
CID: 118513932
Formula: C22H23N7O
MW: 401.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight401.5
XLogP30.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count6
Rotatable Bond Count2
Exact Mass401.19640838
Monoisotopic Mass401.19640838
Topological Polar Surface Area78.1 Ų
Heavy Atom Count30
Formal Charge0
Complexity886
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-109101-01Risdiplam
HY-109101SRisdiplam-d4
HY-109101AS1Risdiplam-hydroxylate-d3
HY-109101AS2Risdiplam-hydroxylate-d6
HY-P2274RArgifin (Standard)
HY-N9362REmodinanthrone (Standard)
HY-N7948RIsomaltotetraose (Standard)
HY-N7640RDeoxylimonin (Standard)
HY-N7617RToralactone (Standard)
HY-N7541RAntrodin A (Standard)

Alternative Products

CatalogName
BA3959-5Risdiplam
CS-O-43408Risdiplam D4
TRC-R369911-50MGRisdiplam D₄
A20300-100Risdiplam 100mg

Popular Products